Conditions · Pancreatic cancer
Pancreatic cancer — clinical trials in France
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
[68Ga]Ga-DPI-4452 · [177Lu]Lu-DPI-4452 — 10 sites
- TRIALNARECRUITING
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)
Detection of circulating tumor cells expressing Axl: CTC-AXL(+) — 1 site
- TRIALPHASE2RECRUITING
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Autogene cevumeran · Atezolizumab · mFOLFIRINOX — 89 sites
- TRIALPHASE2RECRUITING
Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)
68Ga-FAPI-46 for PET / CT scan — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Elironrasib · Daraxonrasib — 55 sites
- TRIALEARLY_PHASE1RECRUITING
B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.
blood plasma sample · blood sampling — 1 site
- TRIALPHASE2RECRUITING
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
ASP3082 — 7 sites
- TRIALNARECRUITING
Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
educational workshop on nutrition + additional intervention on UPF tool and how to use it — 3 sites
- TRIALNANOT_YET_RECRUITING
Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer
APA program — 1 site
- TRIALPHASE1RECRUITING
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
DSB2455 — 18 sites
- TRIALPHASE3RECRUITING
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Tislelizumab · Blood sampling · Placebo — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4) — 2 sites
- TRIALNARECRUITING
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Blood draws — 17 sites
- TRIALNARECRUITING
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)
FNB sampling · blood sampling — 2 sites
- TRIALPHASE1RECRUITING
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
68Ga-NNS309 · 177Lu-DFC413 — 8 sites
- TRIALPHASE2RECRUITING
Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients
GEMBRAX/FOLFIRINOX Arm A · FOLFIRINOX Arm B — 8 sites
- TRIALPHASE3RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101 · Everolimus · Sunitinib — 54 sites
- TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
- TRIALPHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
daraxonrasib — 66 sites
- TRIALPHASE1RECRUITING
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
LY4170156 · bevacizumab · carboplatin — 23 sites
- TRIALPHASE2 / PHASE3RECRUITING
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
SBP-101 · Nab-paclitaxel · Gemcitabine — 93 sites
- TRIALNARECRUITING
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors
Hepatocellular carcinoma · Pancreatic adenocarcinoma · Pancreatic neuroendocrine tumor — 1 site
- TRIALNARECRUITING
Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions
With non-magnetic screen — 1 site
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 220 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
- TRIALPHASE2RECRUITING
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
Dostarlimab · Vitamin D3 (Cholecalciferol) · mFOLFIRINOX Treatment Regimen — 5 sites
- TRIALPHASE2RECRUITING
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Gabrinox · MRI-GUIDED STEREOTACTIC RADIOTHERAPY — 9 sites
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
AZD5863 — 25 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.